BR112021019430A2 - Lisinas e seus derivados com atividade bactericida contra pseudomonas aeruginosa, na presença de soro humano - Google Patents

Lisinas e seus derivados com atividade bactericida contra pseudomonas aeruginosa, na presença de soro humano

Info

Publication number
BR112021019430A2
BR112021019430A2 BR112021019430A BR112021019430A BR112021019430A2 BR 112021019430 A2 BR112021019430 A2 BR 112021019430A2 BR 112021019430 A BR112021019430 A BR 112021019430A BR 112021019430 A BR112021019430 A BR 112021019430A BR 112021019430 A2 BR112021019430 A2 BR 112021019430A2
Authority
BR
Brazil
Prior art keywords
lysines
derivatives
human serum
activity against
pseudomonas aeruginosa
Prior art date
Application number
BR112021019430A
Other languages
English (en)
Portuguese (pt)
Inventor
Raymond Schuch
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of BR112021019430A2 publication Critical patent/BR112021019430A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112021019430A 2019-04-05 2020-04-03 Lisinas e seus derivados com atividade bactericida contra pseudomonas aeruginosa, na presença de soro humano BR112021019430A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830207P 2019-04-05 2019-04-05
PCT/US2020/026681 WO2020206327A1 (en) 2019-04-05 2020-04-03 Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum

Publications (1)

Publication Number Publication Date
BR112021019430A2 true BR112021019430A2 (pt) 2021-11-30

Family

ID=72667504

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019430A BR112021019430A2 (pt) 2019-04-05 2020-04-03 Lisinas e seus derivados com atividade bactericida contra pseudomonas aeruginosa, na presença de soro humano

Country Status (11)

Country Link
US (1) US20220160843A1 (https=)
EP (1) EP3946609A4 (https=)
JP (1) JP2022526978A (https=)
KR (1) KR20210148320A (https=)
CN (1) CN114040773A (https=)
AU (1) AU2020256258A1 (https=)
BR (1) BR112021019430A2 (https=)
CA (1) CA3136126A1 (https=)
IL (1) IL286941A (https=)
MX (1) MX2021012166A (https=)
WO (1) WO2020206327A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24750B1 (es) * 2020-11-19 2025-06-11 Centro De Investig Y Desarrollo De Medicamentos Cidem Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
CN116200418A (zh) * 2021-12-01 2023-06-02 华南农业大学 一种筛选铜绿假单胞菌LasR基因调控网络未知基因突变体的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5701777B2 (ja) * 2009-02-06 2015-04-15 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 抗菌性ファージ、ファージペプチド、及びそれらの使用方法
CA2833409A1 (en) * 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
AU2015279705B2 (en) * 2014-06-26 2021-04-01 The Rockefeller University Acinetobacter lysins
AU2016324307B2 (en) * 2015-09-17 2021-10-21 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
BR112020011433A2 (pt) * 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
CN108103050A (zh) * 2018-02-11 2018-06-01 中国医药集团总公司四川抗菌素工业研究所 一种铜绿假单胞菌噬菌体裂解酶、其编码基因、重组表达载体及其制备方法和应用
CN112368376A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
WO2020046747A1 (en) * 2018-08-23 2020-03-05 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof

Also Published As

Publication number Publication date
MX2021012166A (es) 2021-11-03
CA3136126A1 (en) 2020-10-08
EP3946609A1 (en) 2022-02-09
EP3946609A4 (en) 2023-05-03
US20220160843A1 (en) 2022-05-26
KR20210148320A (ko) 2021-12-07
AU2020256258A1 (en) 2021-11-04
JP2022526978A (ja) 2022-05-27
WO2020206327A1 (en) 2020-10-08
IL286941A (en) 2021-10-31
CN114040773A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
MX2020006098A (es) Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
Boparai et al. Mini review on antimicrobial peptides, sources, mechanism and recent applications
Gottardi et al. N-chloramines, a promising class of well-tolerated topical anti-infectives
Lei et al. The antimicrobial peptides and their potential clinical applications
JP7267251B2 (ja) 抗菌組成物及び医薬組成物
US11690899B2 (en) Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
Rossi et al. Research advances in the development of peptide antibiotics
Blower et al. Snake cathelicidin NA-CATH and smaller helical antimicrobial peptides are effective against Burkholderia thailandensis
TW201239095A (en) Antimicrobial agents
CN115244067A (zh) 合成抗微生物肽
Harris et al. Aberrant action of amyloidogenic host defense peptides: a new paradigm to investigate neurodegenerative disorders?
Carey et al. Human upper airway epithelium produces nitric oxide in response to Staphylococcus epidermidis
BR112021019430A2 (pt) Lisinas e seus derivados com atividade bactericida contra pseudomonas aeruginosa, na presença de soro humano
BR112021025948A2 (pt) Polipeptídeos antimicrobianos derivados de bacteriófagos e seu uso contra bactérias gram-negativas e ácido-resistentes
Lee et al. Chicken NK-lysin is an alpha-helical cationic peptide that exerts its antibacterial activity through damage of bacterial cell membranes
US20160022832A1 (en) Proteas stabilized antibacterial peptides for s. aureus
WO2018155813A3 (ko) 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
Mohan et al. Enhanced antimicrobial activity of peptide-cocktails against common bacterial contaminants of ex vivo stored platelets
Mechesso et al. Enhanced antimicrobial screening sensitivity enabled the identification of an ultrashort peptide KR-8 for engineering of LL-37mini to combat drug-resistant pathogens
Evans et al. A review of antimicrobial peptides: defensins and related cationic peptides
Rouhani et al. A comparison of antibacterial properties of Tachyplesin, Thanatin, and Enterocin P on Enterococcus faecalis
Mbarga et al. Long exposure impact of antibiotics subinhibitory doses and silver nanoparticles on uropathogenic bacteria
WO2021079435A1 (ja) バクテリオファージ組成物
Yuhnev et al. Search of novel antimicrobial peptides of the cathelicidins and defensins families in moose (Alces alces) leucocytes
Maystrenko Comparing the Potency, Stability and Cell Stimulating Activity of Protegrin-1 with a Hybrid Antimicrobial Peptide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.